An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Baoxue Quan, Huiping Shuai, Anjie Xia, Yuxin Hou, Rui Zeng, Xinlei Liu, Guifeng Lin, Jingxin Qiao, Wenpei Li, Falu Wang, Kai Wang, Renjie Zhou, Terrence Tsz‐Tai Yuen, Mingxin Chen, Chaemin Yoon, Ming Wu, Shiyu Zhang, Chong Huang, Yifei Wang, Wei Yang, Chenyu Tian, Weimin Li, Yu-Quan Wei, Kwok‐Yung Yuen, Jasper Fuk‐Woo Chan, Jian Lei, Hin Chu, Shengyong Yang
Topics & Concepts
In vivoProteaseIC50VirusProtease inhibitor (pharmacology)PharmacologyPotencyIn vitroVirologyDrugBioavailabilityViral replicationChemistryBiologyEnzymeViral loadBiochemistryAntiretroviral therapyBiotechnologySARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery Methodsvaccines and immunoinformatics approaches